Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,469
Stocks News & Analysis
stocks
More gas left in the tank for ASX highflyer
stocks
Ahead of Earnings, is Apple stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,127.14 | 15.91 | -0.20% |
| DAX 40 | 24,892.12 | 8.59 | -0.03% |
| Dow JONES (US) | 49,098.71 | 285.30 | -0.58% |
| FTSE 100 | 10,173.36 | 29.92 | 0.29% |
| HKSE | 26,765.52 | 16.01 | 0.06% |
| NASDAQ | 23,501.24 | 65.22 | 0.28% |
| Nikkei 225 | 52,885.25 | 961.62 | -1.79% |
| NZX 50 Index | 13,460.74 | 12.50 | 0.09% |
| S&P 500 | 6,915.61 | 2.26 | 0.03% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,132.60 | 3.56 | -0.09% |